Navigation Links
Zimmer Holdings, Inc. Reports First Quarter Financial Results
Date:4/24/2008

Currency

Sales % Growth % Growth

Geographic Segments

Americas $607 7 % 6 %

Europe 305 18 6

Asia Pacific 147 19 7

Total 1,059 11 6

Product Categories

Reconstructive

Americas 482 7 6

Europe 275 18 6

Asia Pacific 115 19 8

Total 872 12 6

Knees

Americas 280 7 6

Europe 120 18 6

Asia Pacific 54 25 12

Total 454 11 7

Hips

Americas 148 4 3

Europe 129 15 3

Asia Pacific 53 19 6

Total 330 10 3

Extremities 32 31 27

Dental 56 14 9

Trauma 56 11 6

Spine 54 16 14

OSP and other 77 5 1

Net earnings for the first quarter were $239 million on a reported basis and $244 million on an adjusted basis, an increase of 4% adjusted over the prior year period
'/>"/>

SOURCE Zimmer Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results
3. Zimmer Announces Successful Completion of ORTHOsoft Takeover Bid
4. Zimmer Holdings to Present at Upcoming Investor Conferences
5. Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman
6. Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee
7. Zimmer Holdings to Present at JPMorgan Healthcare Conference
8. Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results
9. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
10. Zimmer Reports Fourth Quarter and 2007 Financial Results
11. Zimmer Holdings to Present at Merrill Lynch Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...n (a) levels boost cardiovascular disease risk fo...y News) -- If you,re worried about reducing your r...at you should quit smoking, eat a healthful diet, ...eck, and make sure your cholesterol levels aren,t ...ein (a) levels are? , Well, if you don,t have ...
(Date:10/10/2008)...mpany committed to helping people address health n.../ -- In these troubling,economic times, people may... may feel that they don,t have the money to visit ...a survey by the National Association of,Insurance ... -- Twenty-two percent of Americans say that they ...
(Date:10/10/2008)...Oct. 10 /PRNewswire/ -- Do you think that the blin...d town? Attend the October,17 open house at the Vi...ion Impaired, and see how instructors there empowe...ve, fulfilling lives through non-visual,techniques...1 Azalea Avenue, is holding an open house to,celeb...
(Date:10/10/2008)...omy serving as tipping point for behavior change, ...-- More than half of,Americans (51 percent) believ...are system, but major changes are needed, accordin...urvey was released today by the,Employee Benefit R...tes,Inc., and was underwritten by the Principal Fi...
Breaking Medicine News(10 mins):Health News:Little-Known Fat Can Be a Heartbreaker 2Health News:Little-Known Fat Can Be a Heartbreaker 3Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:Virginia Rehabilitation Center for the Blind and Vision Impaired Celebrates Opening of New Student Dormitory 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3
...diabetes, and arthritis are among a variety of aut... of white blood cell, called the immune regulatory...s malfunction is when a mutation in the FOXP3 gene...In a new study published online this week in the P...
...cted on mice shows that more copper in everyday di...ducted by scientists at the University of Louisvil...esearch Center. Their studies show that giving co...ress on their over-worked hearts by preventing hea...
...cted by American Academy of Neurology finds that e...providing short-term pain relief for lower back pa...long-term pain relief. To develop the guideline, ...c studies on the topic. According to the guidelin...
...time. An extra hour to enjoy life outside. An extr.../ . What should we do when the clock jukes and ji...aves that regulate our sleep? It’s bad enough for... concept. What about kids, who will want to squeez...
Other Medicine News:Health News:Researchers Discover New Molecular Path to Fight Autoimmune Diseases 2Health News:Use Daylight-saving Change to Practice Healthy Sleep Habits 2
(Date:10/8/2008)... LYON, France, Oct. 8 /- Vical In...panded clinical data and new nonclinical data,demo... may be broadly,applicable in DNA- and protein-bas...ancer vaccines. Alain P. Rolland, Pharm.D., Ph.D.,...ent, will present the data today,Wednesday, Octob...
(Date:10/7/2008)... Study evaluates the efficacy of new device for de...issed during colonoscopy, ORLANDO, Fla., Oct. 7 /...terology Annual Scientific Meeting in Orlando (ACG..., MD presented results from a,multi-institutional ...Third,Eye(R) Retroscope(R), a new device that is d...
(Date:10/7/2008)... Study Showed Larazotide Acetate Prevented Immun...n Patients with Celiac Disease, Additional Data In...isease, ORLANDO, Fla., Oct. 7 /- Alb...two clinical studies this week at the American,Col...fic Meeting. Data from,study CLIN 1001-004, the fi...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sci...ire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. (...Inc. (NYSE: FRX ) today announced the presentatio...lotide,s safety and efficacy in 420 patients with,.... Analysis of the data,indicates that once- daily ...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Your belly fat could be making you hungrier 17023 1Your belly fat could be making you hungrier 17023 2GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 1GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 2GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 3The Miracle of Funding by State and Local Pension Plans 17016 1The Miracle of Funding by State and Local Pension Plans 17016 2AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 1AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 2AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 3
...ewswire/ -- A new study,demonstrated that the acti...cg twice a day, may improve symptom relief rates i...pation (IBS-C). These,results were presented as a ...argest annual international meeting of digestive d...eiving lubiprostone were nearly,twice as likely to...
...007 - Results from phase III,clinical trials and f...t the 16th Congress of the European Academy of,Der...ghted the,efficacy and safety profile of alitretin...atients with severe refractory chronic,hand eczema...vere Chronic Hand,Eczema (CHE) refractory or unres...
Other Medicine Technology:New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 2New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 3New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 4New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 5New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 6Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5
...ell (nRBC) control for evaluating the accuracy and... analyzer in its enumeration of the nRBC parameter.... nRBC-Chex for LH is a two-level control packaged...H has a 75-day closed-vial stability and a 14-day ...
...e blood control to test for the presence of Hemogl...horesis. Sickle-Chex is compatible with Streck SIC...Sickle-Chex is packaged in a 2.5ml plastic squeeze...le volume. No pipeting is required. The product do...
...essentially eliminates premature deployment or jum...anatomically designed tapered stent for better fit...xchange catheter with 6 Fr low crossing profile an...er on catheter clearly indicates tapered location ...
... control assayed for all parameters on the Coulter...AcT diff2, MD Series and ONYX Series; Abbott CELL-...0; and Diatron Abacus and Abacus Junior. Para 12 E...six-month closed-vial stability and is available i...
Medicine Products: